China Cardiovascular Diseases Therapeutics Market Analysis

China Cardiovascular Disease Therapeutics Market Executive Analysis

The China cardiovascular disease therapeutics market size is at around $13.07 Bn in 2022 and is projected to reach $25.52 Bn in 2030, exhibiting a CAGR of 8.72% during the forecast period. The expected increase in China's health spending is 8.4% yearly. Rapid increases in services per case of disease and unit cost, which add 4.3 and 2.4 %age points, respectively, will be the primary drivers of the growth. The predicted rapid expansion of inpatient services is the biggest threat to the Chinese healthcare system. By reducing the increase of inpatient service use from 8.2 % per year in 2016 to 3.5 % per year in 2035, three % of the gross domestic product could be saved. Since healthcare reforms were implemented in 2009, China's health infrastructure has improved. More than 95% of China's 1.4 Bn people are now covered through the expansion of basic health insurance programs, which established the largest health safety net in the history of the world.

Cardiovascular Disease (CVD) is believed to affect approximately 330 Mn people in China. The burden of CVD will continue to rise in China due to the dual pressures of population aging and a steady rise in the prevalence of metabolic risk factors. This has led to new standards for CVD prevention and therapy as well as the allocation of medical resources in China.

The main causes of death in China are cardiovascular diseases (CVDs), particularly ischaemic heart disease (IHD) and ischaemic stroke (IS). Cardiovascular mortality may be decreased by treatments for the secondary protection of CVD, such as aspirin, beta-blockers, ACEIs, and statins. In order to reduce the incidence of CVD in China, it is essential to ensure that secondary prevention treatments are widely used. Despite advances in fundamental research for CVDs, China has not yet fully developed its research and development for novel new drugs. On the other hand, medical device and material research and development are progressing quickly. In order to direct the development of oriented cardiomyocytes and to promote electrophysiological homogeneity for engineered cardiac tissues, Chinese researchers also developed super-aligned carbon nanotube heart patches. The super-aligned carbon nanotube-based, single-piece pacemaker electrode could also be used for heart failure myocardial infarction patients receiving cardiac resynchronization treatment.

Market Dynamics

Market Growth Drivers

Cardiovascular diseases are more common in China as a result of the country's aging populace. The demand for therapeutics and treatments for cardiovascular diseases is being driven by this. Cardiovascular diseases are becoming more prevalent in China as a result of the country's population's shifting lifestyle, which includes smoking, unhealthy eating habits, and sedentary behavior. The China cardiovascular disease therapeutics market is being driven by this. The risk factors linked to cardiovascular diseases are becoming more widely known among China's general population. The market for therapeutics for cardiovascular disease is expanding as a result of more people pursuing early diagnosis and treatment.

Market Restraints

The cost of cardiovascular disease treatments in China can be relatively expensive, limiting access to these treatments for some patients. As a result, the China cardiovascular disease therapeutics market's development may be constrained by lower adoption rates. It may be challenging for new drugs and treatments to get authorized in China due to the strict regulatory requirements for therapeutics for cardiovascular disease. Due to this, the market may grow more slowly when innovative therapeutics are developed. The China cardiovascular disease therapeutics market is extremely competitive, with both long-standing companies and recent companies vying for market dominance. As a result, there may be a strain on prices and profit margins, which could slow the market's expansion.

Competitive Landscape

Key Players

• Zhengda Pharmacy (CHN)
• Taiyang Pharmaceutical (CHN)
• Ansi Tailai Pharmacy (CHN)
• Lanrui Boyan Medical (CHN)
• Beijing Handian Pharmacy (CHN)
• AstraZeneca
• Sanofi
• Novartis
• Merck
• Gilead Sciences
• F. Hoffmann-La Roche

Healthcare Policies and Regulatory Landscape

In China, the governmental sector provides the majority of the country's healthcare services, and the government is heavily involved in establishing healthcare regulations. All residents are entitled to universal healthcare coverage, and the government sets most of the reimbursement guidelines for treating cardiovascular diseases. The goals of China's cardiovascular disease treatment reimbursement regulations are to guarantee that patients can finance quality medical care. Drug and medical device prices are established by the government, and they are negotiated with manufacturers to make sure they are reasonable and long-lasting.

The government reimburses for a variety of medications used to manage cardiovascular disease, including statins, antihypertensives, anticoagulants, and antiplatelets. Also protected are medical devices like pacemakers, stents, and implantable cardioverter-defibrillators (ICDs). To keep up with the population's changing healthcare requirements, China's reimbursement policies for treating cardiovascular disease are always changing. The government is also working to increase investment in healthcare infrastructure and to better access to healthcare services in rural areas.